{
  "id": "resp_0eb70d3375eb55fe00693c8ebd84ec8190bf7ad39eaee040f7",
  "object": "response",
  "created_at": 1765576381,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0eb70d3375eb55fe00693c8ebdcdc08190ab17ee603dc1f70e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8ecaeb7881908009035fdacf020c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "Phase 1/2 CDK12 inhibitor triple negative breast cancer"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8eccebc481909e8830970c158aaf",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8ede68408190a05bf530285e8531",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8edf1c348190bdcb21373707408c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8edff9848190addbfc7e8d10b623",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.globenewswire.com/Tracker?data=JWwNq12pVgh9stSRMaI0RuCP8MEXCkE6CdcoWMH84Tlshlv-h7F1Y5pNUzgVFc9zR7RarupEMS-yQlWKJDb0xfg6exS4kGU7P4HCjVz3rVQ%3D"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8ee0b2c881909d2597bde3aa3eb7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8ee1fe808190ae4d12ab89d75739",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8ee2a2208190ab1404cc97db0a15",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8ee46d388190b896160849b40a71",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8ee5074c81909e2869b646c5fcb9",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8ee625f081909cdd204627402233",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 clinicaltrials.gov api v2"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8ee83f148190ba19cfababe24621",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8eed20288190981fb02dfc0776ee",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://clinicaltrials.gov/api/v2/studies/NCT06600789"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8eef2d4081909d9f49f804ec29b2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8f0be1b88190b994d53584a29234",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8f0cf6048190945f15b2b6cf7497",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8f22d6e48190b711e71a8db0632c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8f23b8388190b603e8102377df1b",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8f650c7c819085b55a68dafadad4",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13\" degrader \"Phase 1/2\""
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8f6975c481908ba94e5484ab8544",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0eb70d3375eb55fe00693c8f7a10e0819085d82ec52ca9bac9",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 inhibitor \"Phase 1/2\" breast cancer trial"
      }
    },
    {
      "id": "rs_0eb70d3375eb55fe00693c8f7d5e848190b5882d715e103308",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0eb70d3375eb55fe00693c8fb1955081908e85b0a6b967081e",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": false,\n  \"assets\": [],\n  \"rejected_reason\": \"Candidate identifier \\\"Phase 1/2\\\" is a development-stage label, not a specific drug name/code, trial ID, or patent ID; it cannot uniquely identify a single drug asset to validate.\"\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 41271,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 13316,
    "output_tokens_details": {
      "reasoning_tokens": 13250
    },
    "total_tokens": 54587
  },
  "user": null,
  "metadata": {}
}